The DOI matches its Crossref record; 109 of the 109 references it cites were found in a registry or an index.
Mouse models in oncoimmunology
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Self-citationThe immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Self-citationImmunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223
Calreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216
Self-citationIwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Self-citationIFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
Natural Innate and Adaptive Immunity to Cancer
Vesely, M. D., Kershaw, M. H., Schreiber, R. D., & Smyth, M. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101324 · Cited by 2,101
Self-citationCheckpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898
Self-citationShultz, L. D., Lyons, B. L., Burzenski, L. M., Gott, B., Chen, X., Chaleff, S., Kotb, M., Gillies, S. D., King, M., Mangada, J., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.10.6477 · Cited by 1,728
Combining immunotherapy and targeted therapies in cancer treatment
Vanneman, M., & Dranoff, G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3237 · Cited by 1,586
Immunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050915 · Cited by 1,512
Self-citationAdaptive immunity maintains occult cancer in an equilibrium state
Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007) · Nature · doi:10.1038/nature06309 · Cited by 1,436
Self-citationMYC regulates the antitumor immune response through CD47 and PD-L1
Casey, S. C., Tong, L., Li, Y., Do, R., Walz, S., Fitzgerald, K. N., Gouw, A. M., Baylot, V., Gütgemann, I., Eilers, M., et al. (2016) · Science · doi:10.1126/science.aac9935 · Cited by 1,403
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
Matsushita, H., Vesely, M. D., Koboldt, D. C., Rickert, C. G., Uppaluri, R., Magrini, V. J., Arthur, C. D., White, J. M., Chen, Y.-S., Shea, L. K., et al. (2012) · Nature · doi:10.1038/nature10755 · Cited by 1,288
Self-citationLoi, S., Michiels, S., Salgado, R., Sirtaine, N., Jose, V., Fumagalli, D., Kellokumpu-Lehtinen, P.-L., Bono, P., Kataja, V., Desmedt, C., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu112 · Cited by 1,256
Self-citationBroz, M. L., Binnewies, M., Boldajipour, B., Nelson, A. E., Pollack, J. L., Erle, D. J., Barczak, A., Rosenblum, M. D., Daud, A., Barber, D. L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.007 · Cited by 1,207
Guy, C. T., Webster, M. A., Schaller, M., Parsons, T. J., Cardiff, R. D., & Muller, W. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.10578 · Cited by 1,193
Somatic activation of the K-ras oncogene causes early onset lung cancer in mice
Johnson, L., Mercer, K., Greenbaum, D., Bronson, R. T., Crowley, D., Tuveson, D. A., & Jacks, T. (2001) · Nature · doi:10.1038/35074129 · Cited by 1,179
Immunogenic death of colon cancer cells treated with oxaliplatin
Tesniere, A., Schlemmer, F., Boige, V, Kepp, O., Martins, I., Ghiringhelli, F., Aymeric, L., Michaud, M., Apetoh, L., Barault, L., et al. (2010) · Oncogene · doi:10.1038/onc.2009.356 · Cited by 1,173
Self-citationSalmon, H., Franciszkiewicz, K., Damotte, D., Dieu-Nosjean, M.-C., Validire, P., Trautmann, A., Mami-Chouaib, F., & Donnadieu, E. (2012) · Journal of Clinical Investigation · doi:10.1172/jci45817 · Cited by 1,138
Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?
Coussens, L. M., Zitvogel, L., & Palucka, A. K. (2013) · Science · doi:10.1126/science.1232227 · Cited by 1,079
Self-citationImmunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
Pfirschke, C., Engblom, C., Rickelt, S., Cortez-Retamozo, V., Garris, C., Pucci, F., Yamazaki, T., Poirier-Colame, V., Newton, A., Redouane, Y., et al. (2016) · Immunity · doi:10.1016/j.immuni.2015.11.024 · Cited by 952
Self-citationDevelopment of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chainnull mice
Ishikawa, F., Yasukawa, M., Lyons, B., Yoshida, S., Miyamoto, T., Yoshimoto, G., Watanabe, T., Akashi, K., Shultz, L. D., & Harada, M. (2005) · Blood · doi:10.1182/blood-2005-02-0516 · Cited by 932
Palucka, A. K., & Coussens, L. M. (2016) · Cell · doi:10.1016/j.cell.2016.01.049 · Cited by 843
Development and function of human innate immune cells in a humanized mouse model
Rongvaux, A., Willinger, T., Martinek, J., Strowig, T., Gearty, S. V., Teichmann, L. L., Saito, Y., Marches, F., Halene, S., Palucka, A. K., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.2858 · Cited by 789
The secret ally: immunostimulation by anticancer drugs
Galluzzi, L., Senovilla, L., Zitvogel, L., & Kroemer, G. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3626 · Cited by 670
Self-citationTranslation of the Philadelphia chromosome into therapy for CML
Druker, B. J. (2008) · Blood · doi:10.1182/blood-2008-07-077958 · Cited by 668
The mighty mouse: genetically engineered mouse models in cancer drug development
Sharpless, N. E., & DePinho, R. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2110 · Cited by 661
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer
Schramek, D., Leibbrandt, A., Sigl, V., Kenner, L., Pospisilik, J. A., Lee, H. J., Hanada, R., Joshi, P. A., Aliprantis, A., Glimcher, L., et al. (2010) · Nature · doi:10.1038/nature09387 · Cited by 592
Perforin-Mediated Cytotoxicity Is Critical for Surveillance of Spontaneous Lymphoma
Smyth, M. J., Thia, K. Y. T., Street, S. E. A., MacGregor, D., Godfrey, D. I., & Trapani, J. A. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.5.755 · Cited by 576
Self-citationMulti-stage chemical carcinogenesis in mouse skin: Fundamentals and applications
Abel, E. L., Angel, J. M., Kiguchi, K., & DiGiovanni, J. (2009) · Nature Protocols · doi:10.1038/nprot.2009.120 · Cited by 563
Engineered In Vitro Disease Models
Benam, K. H., Dauth, S., Hassell, B., Herland, A., Jain, A., Jang, K.-J., Karalis, K., Kim, H. J., MacQueen, L., Mahmoodian, R., et al. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040418 · Cited by 554
Caloric restriction mimetics enhance anticancer immunosurveillance
Pietrocola, F., Pol, J., Vacchelli, E., Rao, S., Enot, D. P., Baracco, E. E., Levesque, S., Castoldi, F., Jacquelot, N., Yamazaki, T., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.016 · Cited by 542
Expression of tumour-specific antigens underlies cancer immunoediting
DuPage, M., Mazumdar, C., Schmidt, L. M., Cheung, A. F., & Jacks, T. (2012) · Nature · doi:10.1038/nature10803 · Cited by 529
Iwai, Y. (2004) · International Immunology · doi:10.1093/intimm/dxh194 · Cited by 527
Joshi, N. S., Akama-Garren, E. H., Lu, Y., Lee, D.-Y., Chang, G. P., Li, A., DuPage, M., Tammela, T., Kerper, N. R., Farago, A. F., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.08.006 · Cited by 520
Microbiome and Anticancer Immunosurveillance
Zitvogel, L., Ayyoub, M., Routy, B., & Kroemer, G. (2016) · Cell · doi:10.1016/j.cell.2016.03.001 · Cited by 478
Self-citationChemotherapy-induced antitumor immunity requires formyl peptide receptor 1
Vacchelli, E., Ma, Y., Baracco, E. E., Sistigu, A., Enot, D. P., Pietrocola, F., Yang, H., Adjemian, S., Chaba, K., Semeraro, M., et al. (2015) · Science · doi:10.1126/science.aad0779 · Cited by 452
Self-citationA dual role for autophagy in a murine model of lung cancer
Rao, S., Tortola, L., Perlot, T., Wirnsberger, G., Novatchkova, M., Nitsch, R., Sykacek, P., Frank, L., Schramek, D., Komnenovic, V., et al. (2014) · Nature Communications · doi:10.1038/ncomms4056 · Cited by 442
Self-citationAn Immunosurveillance Mechanism Controls Cancer Cell Ploidy
Senovilla, L., Vitale, I., Martins, I., Tailler, M., Pailleret, C., Michaud, M., Galluzzi, L., Adjemian, S., Kepp, O., Niso-Santano, M., et al. (2012) · Science · doi:10.1126/science.1224922 · Cited by 436
Self-citationThe Emperor of All Maladies: A Biography of Cancer
Mukherjee, S. (2010) · Cited by 416
FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis
Dahan, R., Sega, E., Engelhardt, J., Selby, M., Korman, A. J., & Ravetch, J. V. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.08.004 · Cited by 409
Cancer immunoediting by the innate immune system in the absence of adaptive immunity
O’Sullivan, T., Saddawi-Konefka, R., Vermi, W., Koebel, C. M., Arthur, C., White, J. M., Uppaluri, R., Andrews, D. M., Ngiow, S. F., Teng, M. W. L., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112738 · Cited by 348
Self-citationRakhra, K., Bachireddy, P., Zabuawala, T., Zeiser, R., Xu, L., Kopelman, A., Fan, A. C., Yang, Q., Braunstein, L., Crosby, E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.002 · Cited by 339
Contribution of IL-17–producing γδ T cells to the efficacy of anticancer chemotherapy
Ma, Y., Aymeric, L., Locher, C., Mattarollo, S. R., Delahaye, N. F., Pereira, P., Boucontet, L., Apetoh, L., Ghiringhelli, F., Casares, N., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20100269 · Cited by 337
Self-citationPivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors
Mattarollo, S. R., Loi, S., Duret, H., Ma, Y., Zitvogel, L., & Smyth, M. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0753 · Cited by 333
Self-citationEngelhardt, J. J., Boldajipour, B., Beemiller, P., Pandurangi, P., Sorensen, C., Werb, Z., Egeblad, M., & Krummel, M. F. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.008 · Cited by 330
Natural and therapy-induced immunosurveillance in breast cancer
Kroemer, G., Senovilla, L., Galluzzi, L., André, F., & Zitvogel, L. (2015) · Nature Medicine · doi:10.1038/nm.3944 · Cited by 310
Self-citation50 Years of Preclinical Anticancer Drug Screening: Empirical to Target-Driven Approaches
Suggitt, M., & Bibby, M. C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.971.11.3 · Cited by 298
Immunologic Mechanisms in UV Radiation Carcinogenesis
(1981) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60239-0 · Cited by 288
Kohrt, H. E., Thielens, A., Marabelle, A., Sagiv-Barfi, I., Sola, C., Chanuc, F., Fuseri, N., Bonnafous, C., Czerwinski, D., Rajapaksa, A., et al. (2014) · Blood · doi:10.1182/blood-2013-08-519199 · Cited by 283
DuPage, M., Cheung, A. F., Mazumdar, C., Winslow, M. M., Bronson, R., Schmidt, L. M., Crowley, D., Chen, J., & Jacks, T. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.11.011 · Cited by 244
The Emperor of all Maladies: A Biography of Cancer
Huilgol, N. (2011) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.80439 · Cited by 239
In vivo discovery of immunotherapy targets in the tumour microenvironment
Zhou, P., Shaffer, D. R., Alvarez Arias, D. A., Nakazaki, Y., Pos, W., Torres, A. J., Cremasco, V., Dougan, S. K., Cowley, G. S., Elpek, K., et al. (2014) · Nature · doi:10.1038/nature12988 · Cited by 237
Strowig, T., Rongvaux, A., Rathinam, C., Takizawa, H., Borsotti, C., Philbrick, W., Eynon, E. E., Manz, M. G., & Flavell, R. A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1109769108 · Cited by 228
Zhao, T., Zhang, Z.-N., Westenskow, P. D., Todorova, D., Hu, Z., Lin, T., Rong, Z., Kim, J., He, J., Wang, M., et al. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.07.021 · Cited by 226
CD73-Deficient Mice Are Resistant to Carcinogenesis
Stagg, J., Beavis, P. A., Divisekera, U., Liu, M. C. P., Möller, A., Darcy, P. K., & Smyth, M. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0420 · Cited by 211
Self-citationBenson, D. M., Bakan, C. E., Zhang, S., Collins, S. M., Liang, J., Srivastava, S., Hofmeister, C. C., Efebera, Y., Andre, P., Romagne, F., et al. (2011) · Blood · doi:10.1182/blood-2011-06-360255 · Cited by 208
Sanmamed, M. F., Chester, C., Melero, I., & Kohrt, H. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw041 · Cited by 207
Fucikova, J., Becht, E., Iribarren, K., Goc, J., Remark, R., Damotte, D., Alifano, M., Devi, P., Biton, J., Germain, C., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1142 · Cited by 199
Self-citationTeng, M. W. L., Ngiow, S. F., von Scheidt, B., McLaughlin, N., Sparwasser, T., & Smyth, M. J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1681 · Cited by 192
Self-citationAbate-Daga, D., Lagisetty, K. H., Tran, E., Zheng, Z., Gattinoni, L., Yu, Z., Burns, W. R., Miermont, A. M., Teper, Y., Rudloff, U., et al. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.209 · Cited by 191
Aspord, C., Leccia, M.-T., Charles, J., & Plumas, J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0114-t · Cited by 187
Non-germline genetically engineered mouse models for translational cancer research
Heyer, J., Kwong, L. N., Lowe, S. W., & Chin, L. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2877 · Cited by 179
Sanmamed, M. F., Rodriguez, I., Schalper, K. A., Oñate, C., Azpilikueta, A., Rodriguez-Ruiz, M. E., Morales-Kastresana, A., Labiano, S., Pérez-Gracia, J. L., Martín-Algarra, S., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3510 · Cited by 170
Fisher, T. S., Kamperschroer, C., Oliphant, T., Love, V. A., Lira, P. D., Doyonnas, R., Bergqvist, S., Baxi, S. M., Rohner, A., Shen, A. C., et al. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1237-1 · Cited by 166
Humanized hemato-lymphoid system mice
Theocharides, A. P. A., Rongvaux, A., Fritsch, K., Flavell, R. A., & Manz, M. G. (2016) · Haematologica · doi:10.3324/haematol.2014.115212 · Cited by 166
Xiang, Z., Liu, Y., Zheng, J. H., Liu, M., Lv, A., Gao, Y., Hu, H., Lam, K.-T., Chan, G., Yang, Y., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.026 · Cited by 147
Immunological off-target effects of imatinib
Zitvogel, L., Rusakiewicz, S., Routy, B., Ayyoub, M., & Kroemer, G. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.41 · Cited by 142
Self-citationCharacteristics of tertiary lymphoid structures in primary cancers
Goc, J., Fridman, W. H., Sautès‐Fridman, C., & Dieu‐Nosjean, M. (2013) · OncoImmunology · doi:10.4161/onci.26836 · Cited by 141
Jonkers, J., & Berns, A. J. M. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.12.002 · Cited by 133
Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis
Liu, G., Lu, S., Wang, X., Page, S. T., Higano, C. S., Plymate, S. R., Greenberg, N. M., Sun, S., Li, Z., & Wu, J. D. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69369 · Cited by 122
Lute, K. D., May, K. F., Lu, P., Zhang, H., Kocak, E., Mosinger, B., Wolford, C. C., Phillips, G. S., Caligiuri, M. A., Zheng, P., et al. (2005) · Blood · doi:10.1182/blood-2005-06-2298 · Cited by 118
Combinatorial Cancer Immunotherapies
Hellmann, M. D., Friedman, C. F., & Wolchok, J. D. (2016) · Advances in immunology · doi:10.1016/bs.ai.2015.12.005 · Cited by 116
Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system
Ciampricotti, M., Hau, C., Doornebal, C. W., Jonkers, J., & de Visser, K. E. (2012) · Nature Medicine · doi:10.1038/nm.2652 · Cited by 108
Obenaus, M., Leitão, C., Leisegang, M., Chen, X. T., Gavvovidis, I., van der Bruggen, P., Uckert, W., Schendel, D. J., & Blankenstein, T. J. F. (2015) · Nature Biotechnology · doi:10.1038/nbt.3147 · Cited by 103
Wang, B., Zaidi, N., He, L.-Z., Zhang, L., Kuroiwa, J. M. Y., Keler, T., & Steinman, R. M. (2012) · Breast Cancer Research · doi:10.1186/bcr3135 · Cited by 97
Simpson-Abelson, M. R., Sonnenberg, G. F., Takita, H., Yokota, S. J., Conway, T. F., Kelleher, R. J., Shultz, L. D., Barcos, M. P., & Bankert, R. B. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.10.7009 · Cited by 94
Cancer-driven dynamics of immune cells in a microfluidic environment
Agliari, E., Biselli, E., De Ninno, A., Schiavoni, G., Gabriele, L., Gerardino, A., Mattei, F., Barra, A., & Businaro, L. (2014) · Scientific Reports · doi:10.1038/srep06639 · Cited by 91
γ9 and δ2CDR3 domains regulate functional avidity of T cells harboring γ9δ2TCRs
Gründer, C., van Dorp, S., Hol, S., Drent, E., Straetemans, T., Heijhuurs, S., Scholten, K. B. J., Scheper, W., Sebestyén, Z., Martens, A. C., et al. (2012) · Blood · doi:10.1182/blood-2012-05-432427 · Cited by 89
Aspord, C., Tramcourt, L., Leloup, C., Molens, J., Leccia, M. ‐., Charles, J., & Plumas, J. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.194 · Cited by 79
Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo
Sola, C., André, P., Lemmers, C., Fuséri, N., Bonnafous, C., Bléry, M., Wagtmann, N. R., Romagné, F., Vivier, É., & Ugolini, S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901653106 · Cited by 73
Chang, D.-K., Moniz, R. J., Xu, Z., Sun, J., Signoretti, S., Zhu, Q. K., & Marasco, W. A. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0384-3 · Cited by 72
Datta, J., Rosemblit, C., Berk, E., Showalter, L., Namjoshi, P., Mick, R., Lee, K. P., Brod, A. M., Yang, R. L., Kelz, R. R., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1022301 · Cited by 66
Contribution of IL-17–producing γδ T cells to the efficacy of anticancer chemotherapy
Ma, Y., Aymeric, L., Locher, C., Mattarollo, S. R., Delahaye, N. F., Pereira, P., Boucontet, L., Apétoh, L., Ghiringhelli, F., Casares, N., et al. (2011) · The Journal of Experimental Medicine · doi:10.1084/jem.201002692084c · Cited by 58
Self-citationDay, C., Carter, J., Ohler, Z. W., Bonomi, C., Meskini, R. E., Martin, P., Graff‐Cherry, C., Feigenbaum, L., Tüting, T., Dyke, T. V., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109956 · Cited by 56
Human melanoma immunotherapy using tumor antigen-specific T cells generated in humanized mice
Hu, Z., Xia, J., Fan, W., Wargo, J. A., & Yang, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.7044 · Cited by 47
Mouse Models of Tumor Immunotherapy
Ngiow, S. F., Loi, S., Thomas, D. M., & Smyth, M. J. (2016) · Advances in immunology · doi:10.1016/bs.ai.2015.12.004 · Cited by 44
Self-citationGschweng, E. H., McCracken, M. N., Kaufman, M. L., Ho, M., Hollis, R. P., Wang, X., Saini, N., Koya, R. C., Chodon, T., Ribas, A., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0376 · Cited by 40
Humanized Mice to Study FcγR Function
Bournazos, S., DiLillo, D. J., & Ravetch, J. V. (2014) · Current topics in microbiology and immunology · doi:10.1007/978-3-319-07911-0_11 · Cited by 39
IL-15 suppresses colitis-associated colon carcinogenesis by inducing antitumor immunity
Bahri, R., Pateras, I. S., D’Orlando, O., Goyeneche-Patino, D. A., Campbell, M., Polansky, J. K., Sandig, H., Papaioannou, M. D., Evangelou, K., Foukas, P. G., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2014.1002721 · Cited by 39
Baracco, E. E., Pietrocola, F., Buqué, A., Bloy, N., Senovilla, L., Zitvogel, L., Vacchelli, E., & Kroemer, G. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1139275 · Cited by 27
Self-citationYokota, S. J., Facciponte, J. G., Kelleher, R. J., Shultz, L. D., Loyall, J. L., Parsons, R. R., Odunsi, K. O., Frelinger, J. G., Lord, E. M., Gerber, S. A., et al. (2013) · Europe PMC (PubMed Central) · Cited by 23
Morphometric analysis of immunoselection against hyperploid cancer cells
Bloy, N., Sauvat, A., Chaba, K., Buqué, A., Humeau, J., Pedro, J. M. B., Bui, J. D., Kepp, O., Kroemer, G., & Senovilla, L. (2015) · Oncotarget · doi:10.18632/oncotarget.5400 · Cited by 15
Self-citationWhat Role could Organoids Play in the Personalization of Cancer Treatment?
Francies, H. E., & Garnett, M. J. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.114 · Cited by 15
Generation of improved mouse models for the study of hepatitis C virus
Douglas, D. N., & Kneteman, N. M. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.022 · Cited by 13
Whetstone, R. D., Wittel, U. A., Michels, N. M., Gulizia, J. M., & Gold, B. I. (2015) · Molecular Carcinogenesis · doi:10.1002/mc.22361 · Cited by 13
Cited by
Top 10 Challenges in Cancer Immunotherapy
Hegde, P. S., & Chen, D. S. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.011 · Cited by 2,238
The immune contexture in cancer prognosis and treatment
Fridman, W. H., Zitvogel, L., Sautès–Fridman, C., & Kroemer, G. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.101 · Cited by 2,263
Self-citationRoles of the immune system in cancer: From tumor initiation to metastatic progression
Gonzalez, H., Hagerling, C., & Werb, Z. (2018) · Genes & Development · doi:10.1101/gad.314617.118 · Cited by 2,111
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Sanmamed, M. F., & Chen, L. (2018) · Cell · doi:10.1016/j.cell.2018.09.035 · Cited by 1,392
Mechanisms of resistance to immune checkpoint inhibitors
Jenkins, R. W., Barbie, D. A., & Flaherty, K. T. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.434 · Cited by 1,383
Metadata
- Authors
- Zitvogel, L., Pitt, J. M., Daillère, R., Smyth, M. J., & Kroemer, G.
- Venue
- Nature Reviews Cancer
- Published
- 2016-09-30
- Volume
- 16
- Issue
- 12
- Pages
- 759-773
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2526282664
- Cited by
- 343
- References
- 109
- FWCI
- 4.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.